{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:12:35Z","timestamp":1789726355271,"version":"4.0.1"},"reference-count":31,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Tropical Med Int Health"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To determine, in a randomised placebo\u2010controlled trial, if cutaneous adverse reactions during treatment (CARDT) with Benznidazole occur as often as with Nifurtimox, and whether the dose and duration of treatment change that frequency.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted the EQUITY trial (NCT02369978), allocating <jats:italic>Trypanosoma cruzi<\/jats:italic> seropositive adults with no apparent clinical disease to a 120\u2010day, blinded treatment with Benznidazole, Nifurtimox, or Placebo (ratio 2:2:1). Active treatment groups included either 60\u2010day conventional\u2010dose (60CD) regimens (Benznidazole 300\u2009mg\/day or Nifurtimox 480\u2009mg\/day, followed or preceded by, 60\u2009days of placebo) or 120\u2010day half\u2010dose (120HD) regimens (Benznidazole 150\u2009mg\/day or Nifurtimox 240\u2009mg\/day). CARDT had blinded adjudication as moderate to severe during the follow\u2010up visits.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 307 participants, 42 CARDT (17.1%, 95% confidence interval [CI] 12.6\u201322.4) occurred in 246 receiving active treatment, compared to two CARDT (3.3%, 95% CI 0.0\u201311.3) in 61 participants receiving placebo. In 122 patients treated with Benznidazole, there were 31 CARDT (25.4%, including eight severe), compared to 11 CARDT (8.9%, including four severe) in 124 individuals treated with Nifurtimox (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Among the 125 participants assigned to the 120HD regimen, there were 26 CARDT (20.8%, including six severe), compared to 16 CARDT (13.2%, including six severe) among 121 in the 60CD group (<jats:italic>p<\/jats:italic>\u2009=\u20090.005). The agent\u2010regime interaction was not significant (<jats:italic>p<\/jats:italic>\u2009=\u20090.443). Eleven participants (25%) with CARDT did not complete their treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>CARDT occurred more frequently with Benznidazole treatment, particularly with longer exposure despite the half\u2010dose regimen. Clinicians should consider these differences when discussing treatment options with patients receiving nitro derivative agents.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tmi.14123","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T08:50:10Z","timestamp":1747644610000},"page":"673-684","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cutaneous reactions during treatment with Nifurtimox or Benznidazole among <i>Trypanosoma cruzi<\/i> seropositive adults without symptomatic cardiomyopathy: A safety sub analysis of a placebo\u2010controlled randomised trial"],"prefix":"10.1111","volume":"30","author":[{"given":"Juan Carlos","family":"Villar","sequence":"first","affiliation":[{"name":"Facultad de Ciencias de la Salud Universidad Aut\u00f3noma de Bucaramanga  Bucaramanga Colombia"},{"name":"Centro de Investigaciones Fundaci\u00f3n Cardioinfantil\u2010Instituto de Cardiolog\u00eda  Bogot\u00e1 Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1191-4361","authenticated-orcid":false,"given":"Mar\u00eda Fernanda","family":"Saavedra","sequence":"additional","affiliation":[{"name":"Centro de Investigaciones Fundaci\u00f3n Cardioinfantil\u2010Instituto de Cardiolog\u00eda  Bogot\u00e1 Colombia"},{"name":"Servicio de hepatolog\u00eda cl\u00ednica y medicina interna Cl\u00ednica CES  Medell\u00edn Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6008-5785","authenticated-orcid":false,"given":"Pablo Andr\u00e9s","family":"Berm\u00fadez","sequence":"additional","affiliation":[{"name":"Centro de Investigaciones Fundaci\u00f3n Cardioinfantil\u2010Instituto de Cardiolog\u00eda  Bogot\u00e1 Colombia"},{"name":"Medical and Health Sciences Education Research Group Universidad del Rosario  Bogot\u00e1 Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6030-8128","authenticated-orcid":false,"given":"Eliana V\u00e1quiro","family":"Herrera","sequence":"additional","affiliation":[{"name":"Centro de Investigaciones Fundaci\u00f3n Cardioinfantil\u2010Instituto de Cardiolog\u00eda  Bogot\u00e1 Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2552-9819","authenticated-orcid":false,"given":"Skarlet Marcell","family":"V\u00e1squez","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias de la Salud Universidad Aut\u00f3noma de Bucaramanga  Bucaramanga Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1807-1867","authenticated-orcid":false,"given":"Helena","family":"Arango","sequence":"additional","affiliation":[{"name":"Centro de Investigaciones Fundaci\u00f3n Cardioinfantil\u2010Instituto de Cardiolog\u00eda  Bogot\u00e1 Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0318-8263","authenticated-orcid":false,"given":"Antonia","family":"Camacho","sequence":"additional","affiliation":[{"name":"Centro de Investigaciones Fundaci\u00f3n Cardioinfantil\u2010Instituto de Cardiolog\u00eda  Bogot\u00e1 Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Javier","family":"Olivera","sequence":"additional","affiliation":[{"name":"Grupo de Parasitolog\u00eda Instituto Nacional de Salud  Bogot\u00e1 Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(10)70098-0"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1590\/0037-8682-0248-2013"},{"key":"e_1_2_7_4_1","unstructured":"Treatment of Chagas Disease|Parasites.American Trypanosomiasis (also known as Chagas Disease)|CDC. [cited 2024 Aug 22]. Available from:https:\/\/www.cdc.gov\/chagas\/treatment\/index.html"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1590\/0037-8682-0399-2016"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(96)04128-1"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1998.59.526"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003312"},{"issue":"5","key":"e_1_2_7_9_1","first-page":"CD003463","article-title":"Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection","volume":"2014","author":"Villar JC","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1507574"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30844-6"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30538-8"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw477"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0185033"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/4940796"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx180"},{"issue":"3","key":"e_1_2_7_17_1","first-page":"123","article-title":"Side effects of benznidazole treatment in a cohort of patients with Chagas disease in non\u2010endemic country","volume":"24","author":"Carrilero B","year":"2011","journal-title":"Rev Esp Quimioter"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14451"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx516"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1086\/656917"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.06.006"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003465"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ690"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01357-22"},{"key":"e_1_2_7_25_1","unstructured":"Villar JuanC ElianaV\u2010H V\u00e1squez SkarletM Herrera V\u00edctorM Olivera MarioJ Ramirez JuanD et al.One year efficacy of Benzinidazole or Nifurtimox among asymptomaticTrypanosoma cruziseropositive in Colombia: a placebo\u2010controlled randomized trial.2021[cited 2025 Jan 19]. p. 146. Available from:https:\/\/www.astmh.org\/getmedia\/59a95de8-1a06-49ca-9fd0-286454cc241a\/ASTMH-2021-Annual-Meeting-Abstract-Book.pdf"},{"key":"e_1_2_7_26_1","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE).Common Terminology Criteria for Adverse Events (CTCAE) v5.0.2017[cited 2025 Jan 20]. Available from:https:\/\/www.meddra.org\/"},{"key":"e_1_2_7_27_1","unstructured":"ProgramaE.Reporte de eventos adversos asociados al uso de medicamentos."},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00629-1"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2013.04.003"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2017.01.002"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1342431"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.16-0761"}],"container-title":["Tropical Medicine &amp; International Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tmi.14123","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T01:57:22Z","timestamp":1751421442000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tmi.14123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1111\/tmi.14123"],"URL":"https:\/\/doi.org\/10.1111\/tmi.14123","archive":["Portico"],"relation":{},"ISSN":["1360-2276","1365-3156"],"issn-type":[{"value":"1360-2276","type":"print"},{"value":"1365-3156","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"2025-05-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}